Tandem Diabetes Care (TNDM) Following App Recall Is The Undervalued Case Still Intact

Tandem Diabetes Care (TNDM) is back in focus after initiating a voluntary recall of a beta t:slim iOS mobile app version that failed to pair properly with Abbott FreeStyle Libre 3 Plus sensors.

At a share price of $16.24, Tandem Diabetes Care has seen momentum fade this year, with the 30-day share price return down 7.36% and the year-to-date share price return down 24.64%. This is occurring even though the 1-year total shareholder return is up 9.8%, while longer term total shareholder returns over three and five years remain negative, suggesting that recent product news, including the t:slim app recall, is being weighed against a longer and still uneven recovery story.

Compare this recall driven setback at Tandem Diabetes Care with other health-focused tech stocks on the move by scanning our hand picked 33 healthcare AI stocks.

Tandem Diabetes Care now trades at a beaten up price after the recall noise and a mixed return history. Does that skew the balance toward upside for new capital, or signal that the risk premium is still too thin?

Most Popular Narrative: 44% Undervalued

Against a last close of $16.24, the most followed narrative puts Tandem Diabetes Care's fair value at $29.20, creating a wide gap that investors are now weighing against execution and recall risk.

Broader pharmacy channel expansion and acceleration of pharmacy-based supply sales are expected to lower out-of-pocket costs, increase pump adoption rates, and shift more high-margin recurring supply sales through premium-priced channels, supporting future revenue growth, margin expansion, and improved earnings.

See why 7 investors see Tandem Diabetes Care as 44% undervalued.

Result: Fair Value of $29.20 (UNDERVALUED)

Still, Tandem Diabetes Care faces real pressure if new pump starts are slow against stronger rivals or if pharmacy and international shifts add complexity that crimps margins.

Find out about the key risks to this Tandem Diabetes Care narrative.

Next Steps

Mixed sentiment around Tandem Diabetes Care can be useful if you treat it as a prompt rather than a verdict. Move quickly, review the underlying numbers, and pressure test your own thesis against the 3 key rewards.

Looking for more investment ideas beyond Tandem Diabetes Care?

If you stop with Tandem Diabetes Care, you only see one angle. Use the Simply Wall Street Screener to hunt for fresh opportunities while others stay glued to headlines.

• Target potential upside by scanning a curated 33 high quality undervalued stocks that combine solid fundamentals with prices that sit below their estimated worth.
• Strengthen your income stream by checking a focused 8 dividend fortresses that may help you build more predictable cash flow from payouts.
• Protect your downside by reviewing a 32 resilient stocks with low risk scores designed to spotlight businesses with more resilient risk profiles.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com